105 related articles for article (PubMed ID: 24285763)
1. Pharmacist-physician collaboration for diabetes care: cardiovascular outcomes.
Howard-Thompson A; Farland MZ; Byrd DC; Airee A; Thomas J; Campbell J; Cassidy R; Morgan T; Suda KJ
Ann Pharmacother; 2013 Nov; 47(11):1471-7. PubMed ID: 24285763
[TBL] [Abstract][Full Text] [Related]
2. Pharmacist-led group medical appointments for the management of type 2 diabetes with comorbid depression in older adults.
Taveira TH; Dooley AG; Cohen LB; Khatana SA; Wu WC
Ann Pharmacother; 2011 Nov; 45(11):1346-55. PubMed ID: 22028418
[TBL] [Abstract][Full Text] [Related]
3. Workplace-based cardiovascular risk management by community pharmacists: impact on blood pressure, lipid levels, and weight.
John EJ; Vavra T; Farris K; Currie J; Doucette W; Button-Neumann B; Osterhaus M; Kumbera P; Halterman T; Bullock T
Pharmacotherapy; 2006 Oct; 26(10):1511-7. PubMed ID: 16999661
[TBL] [Abstract][Full Text] [Related]
4. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
6. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist-physician collaboration for diabetes care: the diabetes initiative program.
Farland MZ; Byrd DC; McFarland MS; Thomas J; Franks AS; George CM; Gross BN; Guirguis AB; Suda KJ
Ann Pharmacother; 2013 Jun; 47(6):781-9. PubMed ID: 23656751
[TBL] [Abstract][Full Text] [Related]
8. Achieving cholesterol target in a managed care organization (ACTION) trial.
Straka RJ; Taheri R; Cooper SL; Smith JC
Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of the diabetes initiative program: a pharmacist-physician collaborative care model.
Franklin BE; Farland MZ; Thomas J; McFarland MS; Ray SM; Byrd DC
Ann Pharmacother; 2013 Dec; 47(12):1627-34. PubMed ID: 24259610
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to assess pharmacist- physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan.
Hammad EA; Yasein N; Tahaineh L; Albsoul-Younes AM
J Manag Care Pharm; 2011 May; 17(4):295-303. PubMed ID: 21534640
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN).
McLean DL; McAlister FA; Johnson JA; King KM; Makowsky MJ; Jones CA; Tsuyuki RT;
Arch Intern Med; 2008 Nov; 168(21):2355-61. PubMed ID: 19029501
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
13. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
Jaussi A; Noll G; Meier B; Darioli R
Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
[TBL] [Abstract][Full Text] [Related]
14. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes.
Chan CW; Siu SC; Wong CK; Lee VW
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):57-64. PubMed ID: 21335480
[TBL] [Abstract][Full Text] [Related]
15. Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database.
Sidorenkov G; Voorham J; de Zeeuw D; Haaijer-Ruskamp FM; Denig P
BMJ Qual Saf; 2013 Apr; 22(4):339-47. PubMed ID: 23386729
[TBL] [Abstract][Full Text] [Related]
16. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
17. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Brath H; Wascher TC; Kästenbauer T; Toplak H
MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
[TBL] [Abstract][Full Text] [Related]
18. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials.
Santschi V; Chiolero A; Burnand B; Colosimo AL; Paradis G
Arch Intern Med; 2011 Sep; 171(16):1441-53. PubMed ID: 21911628
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial.
Siaw MYL; Ko Y; Malone DC; Tsou KYK; Lew YJ; Foo D; Tan E; Chan SC; Chia A; Sinaram SS; Goh KC; Lee JY
J Clin Pharm Ther; 2017 Aug; 42(4):475-482. PubMed ID: 28449205
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
Smith MC; Boldt AS; Walston CM; Zillich AJ
Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
